Journal of Medical Ethics 26 (3):188-193 (2000)
Abstract“Run-in” and “washout” periods involving the withholding of medication are widely used in drug research trials in pursuit of both patient safety and scientific reliability. Such no-medication periods can be justified ethically provided that they are apparent to patients, who can thereby properly consent to undergoing them. Less widespread, but still common, is the practice of “single blinding” no-medication periods, concealing them from patients by means of placebo. Whilst all placebos involve a measure of concealment, their use is typically justified in drug research trials by their preserving the uncertainty generated by the random allocation of different treatments within a drug trial; and by the researchers openly declaring both the randomisation process and the chances of receiving placebo. In the single blind placebo “run-in” or “washout”, neither of these conditions is met.This paper considers three possible defences of the practice of using single blind placebo “run-ins” or “washouts” and finds them all to fail; the practice appears ethically unjustified
Similar books and articles
A Limited Defense of Clinical Placebo Deception.Adam J. Kolber - 2007 - Yale Law & Policy Review 26:75-134.
Placebo Treatment is Effective Differently in Different Diseases — but is It Also Harmless? A Brief Synopsis.Thomas R. Weihrauch - 2004 - Science and Engineering Ethics 10 (1):151-155.
Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials.Jeremy Sugarman - 2004 - Science and Engineering Ethics 10 (1):29-35.
What You Don't Know Can Help You: The Ethics of Placebo Treatment.Daniel Groll - 2011 - Journal of Applied Philosophy 28 (2):188-202.
Reexamination of the Ethics of Placebo Use in Clinical Practice.Atsushi Asai & Yasuhiro Kadooka - 2013 - Bioethics 27 (4):186-193.
Implications of Placebo Theory for Clinical Research and Practice in Pain Management.Connie Peck & Grahame Coleman - 1991 - Theoretical Medicine and Bioethics 12 (3).
Placebo in the Investigation of Psychotropic Drugs, Especially Antidepressants.Stanisław Pużyński - 2004 - Science and Engineering Ethics 10 (1):135-142.
Intentional Self-Deception in a Single Coherent Self.W. J. Talbott - 1995 - Philosophy and Phenomenological Research 55 (1):27-74.
Does Self-Deception Involve Intentional Biasing?W. J. Talbott - 1997 - Behavioral and Brain Sciences 20 (1):127-127.
The CIOMS View on the Use of Placebo in Clinical Trials.Juhana E. Idänpään-Heikkilä & Sev Fluss - 2004 - Science and Engineering Ethics 10 (1):23-28.
Uncomfortable Implications: Placebo Equivalence in Drug Management of a Functional Illness.H. M. Evans & A. P. S. Hungin - 2007 - Journal of Medical Ethics 33 (11):635-638.
Control Theory: Placebo-Controlled Drug Trials Have Problems. Active-Controlled Drug Trials Are Not Always the Solution.Beatrice Alexandra Golomb - 2009 - American Journal of Bioethics 9 (9):67-69.
Added to PP
Historical graph of downloads
Citations of this work
A Plea for Pragmatism in Clinical Research Ethics.David H. Brendel & Franklin G. Miller - 2008 - American Journal of Bioethics 8 (4):24 – 31.
Placebo Controls: Scientific and Ethical Issues.Charles J. Kowalski - 2002 - American Journal of Bioethics 2 (2):33 – 34.
References found in this work
No references found.